TABLE 3

Response to Treatment According to Various Patient Subgroups

		Overall response rate		CR
Characteristic	No. of patients	n	%	n	%	Stable disease	Progressive disease
Total number of patients	29^*	15	52	6	20	8	6
Age (y)
≤60	13	7	54	2	15	3	3
>60	16	8	50	4	25	5	3
Histology
Follicular lymphoma	11	9	82	4	36	1^†	1
Mantle cell lymphoma	14	3^‡	21	1	7	7^§	4
Other lymphomas	4	3	75	1	25	0	1
Bone marrow involvement
No	15	11	73	5	33	1	3
Yes (<25%)	14	4	28	1	7	7	3
Prior rituximab treatment
No	9	4	44	3	33	5	0
Yes	20	11	55	3	15	3	6

↵* Two patients were not evaluable.
↵† Patient achieved tumor regression of 35%.
↵‡ In 1 patient with initial bone marrow involvement, restaging of bone marrow was not done to confirm CR.
↵§ Two patients achieved tumor regression between 40% and <50%.